MedTrace Logo

Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer

NCT03765190 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-12-05

No results posted yet for this study

Summary

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using proton radiation therapy in combination with immunotherapy(ie. Programmed cell death protein 1, also known as PD-1 antibody) in multiple metastases.

Conditions

  • Proton Therapy
  • Immunotherapy
  • Neoplasm Metastasis

Interventions

COMBINATION_PRODUCT

Radiation: Proton Therapy+PD-1 Ab

combination of proton radiotherapy with PD-1 antibody

Sponsors & Collaborators

  • YiZhou International Cancer Hospital

    collaborator UNKNOWN

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Xianshu Gao, MD,PhD · Peking University First Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-01-01
Completion
2022-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03765190 on ClinicalTrials.gov